Interpace Biosciences, Inc.

IDXG

US46062X3035

Managed Healthcare

Delayed OTC Markets Other stock markets 20:14:35 24/05/2024 BST			5-day change	1st Jan Change
1.48 ^USD	+7.25%		+8.03%	+37.04%

05-09	Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-07	Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M	MT

Stephen J. Sullivan Will Not Stand for Director of Interpace Biosciences, Inc

August 22, 2019 at 09:28 pm

Stephen J. Sullivan will not stand for Director of Interpace Biosciences, Inc.

Latest news about Interpace Biosciences, Inc.

Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M	03-07	MT
Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-07	CI
Robert Gorman Provides Notice to Interpace Biosciences, Inc. of His Resignation as A Director and as Chairman of the Board, Including as A Member of the Board?s Regulatory Compliance Committee	12-12	CI
Interpace Biosciences, Inc. Announces Resignation of Edward Chan as Class II Director	11-16	CI
Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Interpace Biosciences, Inc. Enters Amendment to Loan Security Agreement with Broadoak Fund V, L.P	27/10/23	CI
Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23	CI
Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Chief Financial Officer	02/08/23	CI
Interpace Biosciences, Inc. Expects to Stop Offering Pancragen Test Due to CMS Decision to End Reimbursement as of July 17, 2023	05/06/23	CI
Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q1 Revenue $9.8M	12/05/23	MT
Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Principal Financial Officer	25/04/23	CI
Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	27/03/23	CI
Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	27/03/23	CI
Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/03/23	CI
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $8.3M	27/03/23	MT
Interpace Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	26/03/23	CI
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q3 Revenue $8.19M	14/11/22	MT
Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Interpace Biosciences CFO Thomas Freeburg Resigns	04/10/22	MT
Interpace Biosciences, Inc. Announces Resignation of Thomas Freeburg as Chief Financial Officer	04/10/22	CI
Interpace Biosciences, Inc. Announces New Clinical Validation Data	01/09/22	CI
Flagship Biosciences, Inc. acquired Interpace Pharma Solutions from Interpace Biosciences, Inc..	30/08/22	CI

Chart Interpace Biosciences, Inc.

Duration

Period

More charts

Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by leveraging the technology in personalized medicine for improved patient diagnosis and management. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, RespriDX, and BarreGEN. PancraGEN is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts. PanDNA is a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors. ThyGeNEXT is for the diagnosis of thyroid cancer from thyroid nodules. RespriDX differentiates lung cancer of primary versus metastatic origin.

Sector

Managed Healthcare

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company